Transplanting islet cells can fix brittle diabetes. Why isn't it available in the U.S.?

C Ricordi, A Japour
{"title":"Transplanting islet cells can fix brittle diabetes. Why isn't it available in the U.S.?","authors":"C Ricordi,&nbsp;A Japour","doi":"10.32113/cellr4_201910_2768","DOIUrl":null,"url":null,"abstract":"<p><p>Type 1 diabetes, which affects 1.25 million American children and adults, and more than 20 million people around the world, is a challenging chronic disease caused by the body's inability to make insulin. Among its most severe forms is brittle diabetes. People with brittle diabetes frequently experience large swings in blood sugar that can quickly move from too high to too low or vice versa. Severely low blood sugar, called hypoglycemia, can cause sudden and unexpected seizures, coma, heart attacks, and even death. Insulin is the main treatment for this common disease. But it isn't a cure. A type of cell transplant that comes close to a cure for some people with type 1 diabetes, a technique pioneered and tested in the United States, is now available in many countries but is still deemed an experimental procedure in the U.S., making it almost impossible to get. More than a decade ago, the United Kingdom's National Health Service approved islet cell transplantation for type 1 diabetes - an approval based on an extensive review of the evidence generated by clinical trials conducted in the United States. Our federal dollars supported that research, and this treatment ought to be available to U.S. citizens. Islet cell transplantation is not a panacea for all forms of type 1 diabetes. And transplantation of any organ, including islet cells, requires the use of anti-rejection drugs that can have a range of adverse side effects. Nevertheless, individuals with severe brittle diabetes who are fully informed of the risks and benefits should have the ability to access this lifesaving treatment option. We fully understand the FDA's efforts to rein in companies marketing unapproved stem cell products that have little or no evidence to support their use and that may put patients at risk. Yet the FDA should stay equally focused on its commitment to approving evidence-based transformative treatments for devastating diseases and conditions, including brittle diabetes.</p>","PeriodicalId":87230,"journal":{"name":"CellR4-- repair, replacement, regeneration, & reprogramming","volume":"7 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025929/pdf/nihms-1057430.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CellR4-- repair, replacement, regeneration, & reprogramming","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32113/cellr4_201910_2768","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/10/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Type 1 diabetes, which affects 1.25 million American children and adults, and more than 20 million people around the world, is a challenging chronic disease caused by the body's inability to make insulin. Among its most severe forms is brittle diabetes. People with brittle diabetes frequently experience large swings in blood sugar that can quickly move from too high to too low or vice versa. Severely low blood sugar, called hypoglycemia, can cause sudden and unexpected seizures, coma, heart attacks, and even death. Insulin is the main treatment for this common disease. But it isn't a cure. A type of cell transplant that comes close to a cure for some people with type 1 diabetes, a technique pioneered and tested in the United States, is now available in many countries but is still deemed an experimental procedure in the U.S., making it almost impossible to get. More than a decade ago, the United Kingdom's National Health Service approved islet cell transplantation for type 1 diabetes - an approval based on an extensive review of the evidence generated by clinical trials conducted in the United States. Our federal dollars supported that research, and this treatment ought to be available to U.S. citizens. Islet cell transplantation is not a panacea for all forms of type 1 diabetes. And transplantation of any organ, including islet cells, requires the use of anti-rejection drugs that can have a range of adverse side effects. Nevertheless, individuals with severe brittle diabetes who are fully informed of the risks and benefits should have the ability to access this lifesaving treatment option. We fully understand the FDA's efforts to rein in companies marketing unapproved stem cell products that have little or no evidence to support their use and that may put patients at risk. Yet the FDA should stay equally focused on its commitment to approving evidence-based transformative treatments for devastating diseases and conditions, including brittle diabetes.

移植胰岛细胞可以治疗脆性糖尿病。为什么在美国买不到呢?
1型糖尿病是一种具有挑战性的慢性疾病,由身体无法制造胰岛素引起,影响着125万美国儿童和成人,以及全球超过2000万人。其中最严重的是脆性糖尿病。患有脆性糖尿病的人经常经历血糖的大幅波动,可以迅速从过高到过低,反之亦然。严重的低血糖,被称为低血糖症,会导致突然和意外的癫痫发作、昏迷、心脏病发作,甚至死亡。胰岛素是治疗这种常见病的主要药物。但这不是一种治疗方法。有一种细胞移植技术几乎可以治愈一些1型糖尿病患者,这种技术是在美国首创和测试的,现在在许多国家都可以使用,但在美国仍被视为实验程序,几乎不可能获得。十多年前,英国国家卫生服务批准了胰岛细胞移植治疗1型糖尿病——这一批准是基于对在美国进行的临床试验所产生的证据的广泛审查。我们的联邦资金支持了这项研究,这种治疗应该对美国公民开放。胰岛细胞移植并不是治疗所有1型糖尿病的灵丹妙药。任何器官的移植,包括胰岛细胞,都需要使用抗排斥药物,而这种药物会产生一系列的副作用。然而,患有严重脆性糖尿病的人,如果充分了解其风险和益处,应该有能力获得这种挽救生命的治疗选择。我们完全理解FDA控制公司销售未经批准的干细胞产品的努力,这些产品几乎没有或根本没有证据支持其使用,并且可能使患者处于危险之中。然而,FDA应该同样专注于其批准以证据为基础的治疗破坏性疾病和病症的承诺,包括脆性糖尿病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信